SEC Form 3 · accession 0001193805-19-000020
Arcturus Therapeutics Ltd. · ARCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pad Chivukula
Officer — Chief Scientific Officer & COO
Period of report
Jan 1, 2019
Accepted (ET)
Jan 2, 2019 · 6:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | holding | — | — | — | 732,548 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (right to purchase)F1,F2,F3 | $8.00 | holding | — | — | — | — | Aug 23, 2028 | Ordinary Shares | 80,000 | — | D |
Explanation of responses
- F1The Reporting Person is filing this form in connection with the Issuer's transition from reporting as a foreign private issuer to reporting as a domestic issuer, effective January 1, 2019.
- F2183,137 of such shares are subject to repurchase by the Issuer.
- F3Vesting over a period of four years from August 24, 2018, with 25% of the options vesting on the first anniversary thereof and the remainder vesting in equal monthly installments thereafter.